UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 1)
Sabratek Corporation
- -----------------------------------------------------------------
(Name of Issuer)
(Common Stock)
- -----------------------------------------------------------------
(Title of Class of Securities)
78571U 10 8
- -----------------------------------------------------------------
(CUSIP Number)
James A. Meer
Schein Pharmaceutical, Inc.
100 Campus Drive
Florham Park, New Jersey 07932
(201) 593-5500
- -----------------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)
August 20, 1997
- -----------------------------------------------------------------
(Date of Event which Requires Filing of this Statement
If the filing person has previously filed a statement on Schedule
13G to report the acquisition which is the subject of this
Schedule 13D, and is filing this schedule because of Rule 13d-
1(b)(3) or (4), check the following box / /.
The remainder of this cover page shall be filled out for a
reporting person's initial filing on this form with respect to
the subject class of securities, and for any subsequent amendment
containing information which would alter disclosure provided in a
prior cover page.
The information required on the remainder of this cover page
shall not be deemed to be "filed" for the purpose of Section 18
of the Securities Exchange Act of 1934 ("Act") or otherwise
subject to the liabilities of that section of the Act but shall
be subject to all other provisions of the Act (however, see the
Notes).<PAGE>
Schedule 13D
CUSIP NO. 78571U 10 8
- -----------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Schein Pharmaceutical, Inc.
- -----------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) /*/
(b) / /
- -----------------------------------------------------------------
3 SEC USE ONLY
- -----------------------------------------------------------------
4 SOURCE OF FUNDS*
WC
- -----------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) or 2(a) / /
- -----------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
- -----------------------------------------------------------------
NUMBER OF 7 SOLE VOTING POWER
SHARES 0
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH ---------------------------------------------
8 SHARED VOTING POWER
493,361
---------------------------------------------
9 SOLE DISPOSITIVE POWER
0
---------------------------------------------
10 SHARED DISPOSITIVE POWER
493,361
---------------------------------------------
<PAGE>
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
493,361
- -----------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES* / /
- -----------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
4.8%
- -----------------------------------------------------------------
14 TYPE OF REPORTING PERSON IN
CO
- -----------------------------------------------------------------
<PAGE>
Schedule 13D
CUSIP NO. 78571U 10 8
- -----------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Marsam Pharmaceuticals Inc.
- -----------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) /*/
(b) / /
- -----------------------------------------------------------------
3 SEC USE ONLY
- -----------------------------------------------------------------
4 SOURCE OF FUNDS*
AF
- -----------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) or 2(a) / /
- -----------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
- -----------------------------------------------------------------
NUMBER OF 7 SOLE VOTING POWER
SHARES 0
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH ---------------------------------------------
8 SHARED VOTING POWER
493,361
---------------------------------------------
9 SOLE DISPOSITIVE POWER
0
---------------------------------------------
10 SHARED DISPOSITIVE POWER
493,361
---------------------------------------------
<PAGE>
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
493,361
- -----------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES* / /
- -----------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
4.8%
- -----------------------------------------------------------------
14 TYPE OF REPORTING PERSON IN
CO
- -----------------------------------------------------------------
<PAGE>
Schedule 13D
CUSIP NO. 78571U 10 8
- -----------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
MSI, Inc. I.R.S. I.D.# 11-2718-528
- -----------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) /*/
(b) / /
- -----------------------------------------------------------------
3 SEC USE ONLY
- -----------------------------------------------------------------
4 SOURCE OF FUNDS*
AF
- -----------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) or 2(a) / /
- -----------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
- -----------------------------------------------------------------
NUMBER OF 7 SOLE VOTING POWER
SHARES 0
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH ---------------------------------------------
8 SHARED VOTING POWER
493,361
---------------------------------------------
9 SOLE DISPOSITIVE POWER
0
---------------------------------------------
10 SHARED DISPOSITIVE POWER
493,361
---------------------------------------------
<PAGE>
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
493,361
- -----------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES* / /
- -----------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
4.8%
- -----------------------------------------------------------------
14 TYPE OF REPORTING PERSON IN
CO
- -----------------------------------------------------------------
<PAGE>
Item 5. Interest in Securities of the Issuer
The response to Item 5 is hereby amended by deleting the
entire text thereof and substituting the following:
MSI may be deemed to own beneficially 493,361 shares of
Sabratek Common Stock (approximately 4.8% of the Sabratek Common
Stock outstanding), including 318,667 shares subject to a warrant
from the Issuer which is exercisable at any time until September
12, 1999 at a price of $4.55 per share, subject to adjustment.
The percentage of Sabratek Common Stock outstanding has been
calculated based upon information contained in the Issuer's Form
10-Q for the quarter ended June 30, 1997, as filed pursuant to
the Securities Exchange Act of 1934, as amended.
As Marsam is the parent corporation of MSI and Schein is the
parent corporation of Marsam, each of Schein, Marsam and MSI may
be deemed to be beneficial owners of the 493,361 shares of
Sabratek Common Stock with shared voting and dispositive power.
As the Reporting Persons own less than five percent of the
outstanding shares of Sabratek Common Stock as a result of the
sales reported below, the Reporting Persons' filing obligation
terminates with this filing.
Set forth below is certain information with respect to sales
of Sabratek Common Stock by MSI on the Nasdaq National Market,
which sales constitute the only transactions in the Sabratek
Common Stock by any of the Reporting Persons during the last 60
days:
Date Number of Shares Price Per Share
- ---- ---------------- ----------------
August 5, 1997 20,000 $ 29.50
August 6, 1997 80,000 $ 29.90
August 13, 1997 47,500 $ 31.0526
August 14, 1997 5,000 $ 31.125
August 19, 1997 12,500 $ 31.00
<PAGE>
SIGNATURE
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this
Amendment No. 1 is true, complete and correct.
Dated: August 20, 1997
MSI, INC.
By: /s/ James A. Meer
-----------------------
James A. Meer
Authorized Officer
MARSAM PHARMACEUTICALS INC.
By: /s/ James A. Meer
-----------------------
James A. Meer
Authorized Officer
SCHEIN PHARMACEUTICAL, INC.
By: /s/ James A. Meer
--------------------------
James A. Meer
Authorized Officer
